Drug intelligence / Profile preview

EDP2939

Development stage: Phase 1
Lead developer: Evelo Biosciences
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

EDP2939 is an orally delivered, investigational extracellular vesicle (EV) candidate that was developed by Evelo Biosciences. [2] It is manufactured from a single strain of the bacterium *Prevotella histicola*. [5, 8] The drug is designed to act on the small intestinal axis (SINTAX) to resolve inflammation. [2, 3] Its proposed mechanism involves acting in the small intestine to induce systemic regulatory T cells, which then modulate inflammation throughout the body. [5] EDP2939 was being evaluated for the treatment of moderate psoriasis. [2, 3] In October 2023, Evelo Biosciences announced that the Phase 2 clinical study of EDP2939 in moderate psoriasis did not meet its primary endpoint. [1, 3] Consequently, the company ceased the development of EDP2939 and initiated a process to explore strategic alternatives. [1, 4]

Targets

IL10RA (Interleukin-10 Receptor)TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on EDP2939.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDP2939.

Explore the full profile